Vor Biopharma Inc. (VOR): Price and Financial Metrics

Vor Biopharma Inc. (VOR): $1.71

0.03 (+1.79%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add VOR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#119 of 362

in industry

VOR Price/Volume Stats

Current price $1.71 52-week high $5.70
Prev. close $1.68 52-week low $1.62
Day low $1.66 Volume 199,000
Day high $1.74 Avg. volume 295,439
50-day MA $2.05 Dividend yield N/A
200-day MA $2.29 Market Cap 116.65M

VOR Stock Price Chart Interactive Chart >


Vor Biopharma Inc. (VOR) Company Bio


Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.


VOR Latest News Stream


Event/Time News Detail
Loading, please wait...

VOR Latest Social Stream


Loading social stream, please wait...

View Full VOR Social Stream

Latest VOR News From Around the Web

Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 34,313 shares of Vor Bio’s common stock to four newly hired employees. The foregoing s

Yahoo | December 1, 2023

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio’s approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label

Yahoo | November 9, 2023

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update. “We look forward to imminent data releases b

Yahoo | November 7, 2023

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Stifel 2023 Healthcare ConferenceFireside Chat: Tuesday, November 14, 2023 at 3:35 pm ET Location: Lotte New York Palace Hotel, New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. 6th Annual Evercore ISI

Yahoo | November 3, 2023

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children's Hospital of Philadelphia, to discuss abstracts today, November 2, at 9.30 AM ET. CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, toda

Yahoo | November 2, 2023

Read More 'VOR' Stories Here

VOR Price Returns

1-mo -11.40%
3-mo -28.75%
6-mo -15.76%
1-year -63.07%
3-year -94.24%
5-year N/A
YTD -24.00%
2023 -66.17%
2022 -42.77%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!